National Institute on Drug Abuse


Also found in: Acronyms, Wikipedia.

National Institute on Drug Abuse

 (NIDA)
an institute of the national institutes of health that seeks to bring the power of science to bear on drug abuse and addiction through support and conduct of research across a broad range of disciplines, with rapid and effective dissemination of results of the research.

National Institute on Drug Abuse (NIDA)

an institute of the National Institutes of Health that seeks to bring the power of science to bear on drug abuse and addiction through support and conduct of research across a broad range of disciplines, with rapid and effective dissemination of results of the research.
References in periodicals archive ?
Tsung-Ping Su, Professor of National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA), U.
New research by the National Institute on Drug Abuse (NIDA) and other federal agencies is revealing a troubling rise in prescription drug abuse among young people--and among adults as well.
Charles Schuster of the National Institute on Drug Abuse.
3, 2013, the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced today.
The National Institute on Drug Abuse (NIDA) seeks to broaden the understanding of all aspects of inhalant abuse (i.
Institute for Social Research, University of Michigan, Monitoring the Future National Survey Results on Drug Use, 1975-2002, Volume I, Secondary School Students (2003); National Institute on Drug Abuse, http://monitoringthefuture.
Meanwhile, for the first time since the government began keeping records six years ago, ecstasy use dropped among teenagers in 2002, according to the National Institute on Drug Abuse.
The National Institute on Drug Abuse has remarked favorably on these striking results.
A guide to preventing drug abuse among young people, which is based on successful anti-drug programs, is being made available to parents, teachers and community groups by the National Institute on Drug Abuse.
Two research groups -- one led by Shoichi Shimada of the National Institute on Drug Abuse in Baltimore, the other by John E.
announced today that it has signed a five-year Cooperative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health, to study the company's novel anticonvulsant product, vigabatrin, for the treatment of cocaine and methamphetamine dependence.
The National Institute on Drug Abuse (NIDA) is interested in the influence of genetic variation on metabolic, homeostatic, neurocognitive, and physiological responses to abused drugs, as well as the safety and efficacy of drugs used for the treatment of addiction, dependence, and withdrawal, and in drug-drug interactions (e.
Medical browser ?
Full browser ?